Capricor Therapeutics Inc (CAPR)
NASDAQ · Manufacturing · Pharmaceutical preparations
CAPR price, last 12 months
Key stats
- Previous close
- $8.57
- Open
- $8.61
- Day range
- $8.30 – $8.67
- 52-week range
- $2.96 – $40.37
- Volume
- 1.9M
- Avg volume (20 days)
- 3.3M
- Market cap
- $486.0M
Performance
Technicals and fundamentals
About Capricor Therapeutics Inc
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $486.0M